Waxman Calls for Modification of Biologics Exclusivity Period

Rep. Henry Waxman (D-Calif.) is vowing to amend the 12-year period of exclusivity granted to manufacturers of brand biologics in healthcare overhaul legislation earlier this year. The congressman said at the World Generic Medicines Congress Americas 2010 that the legislation as written would not help lower the cost of biologics and he would fight to have it changed. “The legislation did not balance appropriately the incentives for innovation with the incentives for competition,” Waxman said. “This was clearly an opportunity lost.”
Generic Line<